Firsekibart

DRUG4 trials

Sponsors

Ruijin Hospital, Chinese SLE Treatment And Research Group, Second Affiliated Hospital, School of Medicine, Zhejiang University, Children's Hospital of Fudan University

Conditions

Gout FlareKawasaki DiseaseLupus Erythematosus, SystemicStill's Disease, Adult-Onset

Phase 2

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

Not yet recruitingNCT07686770

Children's Hospital of Fudan UniversityKawasaki Disease

Start: 2026-08-01End: 2028-02-01Target: 90Updated: 2026-07-27

Phase 4

Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus

Active, not recruitingNCT07381465

Chinese SLE Treatment And Research GroupLupus Erythematosus, Systemic

Start: 2026-06-16End: 2027-12-31Target: 15Updated: 2026-07-15

Unknown Phase

A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease

RecruitingNCT07191444

Ruijin HospitalStill's Disease, Adult-Onset

Start: 2025-09-24End: 2027-07-31Target: 20Updated: 2026-04-13

24-Week Recurrence Rate of Gout Following Firsekibart Treatment

Not yet recruitingNCT07625514

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityGout Flare

Start: 2026-05-07End: 2029-08-28Target: 264Updated: 2026-06-04